Electronic Supplementary Material

Decreases in both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children

Ran Wang[1#], Lyu Xie[2#], Na Gao[1], Dongying Fan[1], Hui Chen[1], Peigang Wang[1], Hongning Zhou[2✉], Jing An[1,3✉]

1. Department of Microbiology, School of Basic Medical Sciences, Chinese Capital Medical University, Beijing 100069, China
2. Yunnan Provincial Key Laboratory of Vector-borne Disease Control and Research, Yunnan Institute of Parasitic Diseases, Pu'er 665000, PR China
3. Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing 100069, China

Supplementary Table S1 Seroprevalence of antibodies against Japanese encephalitis virus detected by ELISA.

Variable	No. of total cases	No. of total seropositive cases [a] (% in this group)	χ^2 value (P value)	No. of male cases	No. of male seropositive cases [a] (% in this group)	χ^2 value (P value)	No. of female cases	No. of female seropositive cases [a] (% in this group)	χ^2 value (P value)
Overall	300	138 (46%)	-						
Gender									
Male	142	65 (46%)	0.006 (1.000) [b]						
Female	158	73 (46%)							
Year post-booster vaccination [c]									
0.5–1.5	17	14 (82%)	**7.447 (0.006)** [d]	5	4 (80%)	**3.979 (0.049)** [d]	12	10 (83%)	3.507 (0.064) [d]
1.5–2.5	34	16 (47%)		17	9 (53%)		17	7 (41%)	
2.5–3.5	62	32 (52%)		24	12 (50%)		38	20 (53%)	
3.5–4.5	58	25 (43%)		29	15 (52%)		29	10 (34%)	
4.5–5.5	46	19 (41%)		21	8 (38%)		25	11 (44%)	
5.5–6.5	40	16 (40%)		23	9 (39%)		17	7 (41%)	
6.5–7.5	23	10 (43%)		11	4 (36%)		12	6 (50%)	
7.5–8.5	20	6 (30%)		12	4 (33%)		8	2 (25%)	

[a]According to the instructions of the ELISA kit.

[b]χ^2 and P values were calculated with the Chi-square test. $P < 0.05$ was considered significant.

[c]Years post-booster vaccination (by 1-year classes) was defined as the time to the sample collection date on 22 June 2017.

[d]χ^2 and P values were calculated by linear-by-linear association. $P < 0.05$ was considered significant.

Table S2 Seroprevalence of antibodies against Japanese encephalitis virus detected by $PRNT_{50}$.

Variable	No. of total cases	No. of total seropositive cases [a] (% in this group)	χ^2 value (P value)	No. of male cases	No. of male seropositive cases [a] (% in this group)	χ^2 value (P value)	No. of female cases	No. of female seropositive cases [a] (% in this group)	χ^2 value (P value)
Overall	300	107 (36%)	-						
Gender									
Male	142	49 (35%)	0.158 (0.718) [b]						
Female	158	58 (37%)							
Years post-booster vaccination [c]									
0.5–1.5	17	14 (82%)	**10.103 (0.001)** [d]	5	4 (80%)	3.821 (0.055) [d]	12	10 (83%)	**6.190 (0.014)** [d]
1.5–2.5	34	15 (44%)		17	8 (47%)		17	7 (41%)	
2.5–3.5	62	24 (39%)		24	9 (38%)		38	15 (39%)	
3.5–4.5	58	14 (24%)		29	9 (31%)		29	5 (17%)	
4.5–5.5	46	17 (37%)		21	7 (33%)		25	10 (40%)	
5.5–6.5	40	11 (28%)		23	5 (22%)		17	6 (35%)	
6.5–7.5	23	7 (30%)		11	3 (27%)		12	4 (33%)	
7.5–8.5	20	5 (25%)		12	4 (33%)		8	1 (13%)	

[a]Defined as a $PRNT_{50} \geq 1:10$ using Vero cells.

[b]χ^2 and P values were calculated using the Chi-square test. $P < 0.05$ was considered significant.

[c]Years post-booster vaccination (by 1-year classes) was defined as the time to the sample collection date on 22 June 2017.

[d]χ^2 and P values were calculated using the linear-by-linear association. $P < 0.05$ was considered significant.

Table S3 Categories of anti-JEV nAb titres against Japanese encephalitis virus.

Variable	No. of total cases	Seronegative [a] (% in this group)	Low [a] (% in this group)	Medium [a] (% in this group)	High [a] (% in this group)	Geometric mean titre
Years post-booster vaccination [b]						
0.5–1.5	17	3 (18%)	10 (59%)	4 (23%)	0 (0%)	1:28.9
1.5–2.5	34	19 (56%)	12 (35%)	3 (9%)	0 (0%)	1:12.8
2.5–3.5	62	38 (61%)	20 (32%)	4 (7%)	0 (0%)	1:10.8
3.5–4.5	58	44 (76%)	14 (24%)	0 (0%)	0 (0%)	1:7.8
4.5–5.5	46	29 (63%)	15 (33%)	2 (4%)	0 (0%)	1:10
5.5–6.5	40	29 (72%)	9 (23%)	2 (5%)	0 (0%)	1:8.4
6.5–7.5	23	16 (70%)	7 (30%)	0 (0%)	0 (0%)	1:8.3
7.5–8.5	20	15 (75%)	5 (25%)	0 (0%)	0 (0%)	1:7.3

[a]Defined as the $PRNT_{50}$ using Vero cells. Seronegative = titre range < 1:10, low = titre range 1:10-1:40, medium = titre range 1:40-1:160, high = titre range > 1:160

[b]Years post-booster vaccination (by 1-year classes) were defined as the time to the sample collection date on 22 June 2017.